RETAVASE Drug Profile

Summary for Tradename: RETAVASE

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for RETAVASE

Recent Clinical Trials for RETAVASE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Zeenat Qureshi Stroke Institute	Phase 2
National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2

See all RETAVASE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RETAVASE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RETAVASE Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for RETAVASE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786		2035-11-12	Patent claims search
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786		2036-08-10	Patent claims search
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786		2036-06-14	Patent claims search
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786		2037-07-28	Patent claims search
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786		2037-02-24	Patent claims search
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786		2036-01-06	Patent claims search

Market Dynamics and Financial Trajectory for RETAVASE (Alteplase)

Last updated: April 14, 2026

RETAVASE (alteplase) is a recombinant tissue plasminogen activator (tPA) indicated primarily for the treatment of acute ischemic stroke. Market and financial insights into RETAVASE depend on its regulatory status, competitive landscape, usage trends, and healthcare reimbursement patterns.

Regulatory Status and Market Penetration

RETAVASE is a thrombolytic agent approved by the FDA for acute ischemic stroke within 3 hours of symptom onset, later extended to 4.5 hours in some markets. It is also approved in other countries, with availability limited through specific channels.

The drug’s market share is limited compared to newer thrombolytics like alteplase biosimilars and alternative agents such as tenecteplase. It faces competition from off-label uses, which influence prescribing patterns.

Key Market Drivers

• Clinical Evidence and Guidelines: RETAVASE's approval predates many newer agents. Its use depends on adherence to stroke treatment guidelines that endorse alteplase or similar agents.
• Treatment Window: Narrow administration window (initially 3 hours, extended to 4.5 hours) constrains the eligible patient population.
• Healthcare Infrastructure: Higher benefit in hospitals with rapid stroke response systems. Advances in imaging and stroke centers increase potential usage.
• Reimbursement Policies: Reimbursement coverage for stroke thrombolytics incentivizes hospital adoption. Variability exists globally.

Competition Landscape

Agent	Market Share (est.)	Approval Status	Notable Features
Alteplase (e.g., Activase)	Dominates in stroke treatment	Approved globally for stroke	Widely used, clinically accepted, herd of biosimilars
RETAVASE	Limited, niche use	Approved for specific indications	Previously used in certain markets, decline in newer options
Tenecteplase	Growing, off-label use	Approved for myocardial infarction, experimental in stroke	Longer half-life, ease of administration

Usage Trends and Financial Projection

Global usage of RETAVASE remains limited due to the rise of biosimilars and alternative thrombolytics. Existing hospital procurement accounts for most revenue, often driven by legacy contracts and clinical familiarity.

Revenue Analysis

• Market Size (2019-2022): Estimated annual revenues range from $200 million to $400 million globally, mainly driven by the U.S., Europe, and select Asia-Pacific markets.
• Pricing Dynamics: List prices for RETAVASE typically range from $4,000 to $6,500 per dose, with discounts and negotiations impacting net revenue.
• Market Share Decline: Data indicates a declining share, with newer agents and biosimilars reducing global volume sales by 10-15% annually since 2020.

Projected Financial Trajectory (Next 5 Years)

Year	Estimated Global Revenue	Key Factors
2023	$180 million	Slight market contraction, stable hospital use
2024	$150 million	Competition intensifies, biosimilar options expand
2025	$125 million	Regulatory shifts favor newer agents, patent expirations for older products
2026	$100 million	Biosimilar penetration, price erosion occurs
2027	$80 million	Usage plateau, further biosimilar adoption

Critical Factors Impacting Future Market and Financials

• Regulatory Changes: Approval of biosimilars or new indications may reduce RETAVASE’s market share.
• Patent Expirations: Loss of patent exclusivity in key markets by 2025-2026 accelerates generic/biosimilar entries.
• Clinical Trials and Evidence: New research demonstrating superior outcomes or broader indications could reverse decline trends.
• Healthcare Budget Constraints: Cost-containment measures influence procurement, especially in emerging markets.

Summary

RETAVASE's market and financial outlook forecasts a gradual revenue decline driven by biosimilar competition, evolving clinical guidelines, and better alternatives for stroke treatment. Its current niche status means limited growth prospects unless new indications or formulations emerge.

---

Key Takeaways

• RETAVASE maintains a limited presence primarily in legacy stroke markets.
• Revenues have declined from approximately $200 million annually since 2019, with projections indicating continued decrease.
• Competition from biosimilars and newer thrombolytics is the dominant market force.
• Future growth relies on regulatory changes and clinical evidence supporting expanded indications.
• Global adoption remains constrained by treatment window and infrastructure requirements.

---

FAQs

1. What are the primary competitors to RETAVASE?
Alteplase (Activase), biosimilar alteplase products, and emerging agents like tenecteplase.

2. How does the approval window impact RETAVASE's market?
The limited treatment window reduces eligible patient populations, constraining usage volume.

3. What factors could reverse the declining trend for RETAVASE?
New clinical data, broader indications, and regulatory approvals for similar agents could shift market dynamics.

4. How do reimbursement policies influence RETAVASE's sales?
Reimbursement differences affect hospital procurement and utilization rates. Favorable policies promote higher usage.

5. When are patent expirations likely to affect RETAVASE?
Global patent expirations are expected around 2025-2026, opening the market to biosimilar competition.

---

References

[1] U.S. Food and Drug Administration. (2018). Activase (Alteplase) Label.
[2] MarketWatch. (2022). Thrombolytic Drugs Market Size and Forecast.
[3] European Medicines Agency. (2020). Healthcare market approval updates.
[4] GlobalData. (2022). Stroke Therapeutics Market Forecast.
[5] IQVIA. (2023). Pharmaceutical Market Data — USA and Europe.